Eli Lilly and Co (LLY)
732.20
-13.49
(-1.81%)
USD |
NYSE |
Apr 24, 16:00
725.21
-6.99
(-0.95%)
Pre-Market: 04:27
Eli Lilly Debt to Equity Ratio: 2.342 for Dec. 31, 2023
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
Date | Value |
---|---|
December 31, 2023 | 2.342 |
September 30, 2023 | 1.798 |
June 30, 2023 | 1.701 |
March 31, 2023 | 1.688 |
December 31, 2022 | 1.525 |
September 30, 2022 | 1.578 |
June 30, 2022 | 1.968 |
March 31, 2022 | 1.769 |
December 31, 2021 | 1.880 |
September 30, 2021 | 2.203 |
June 30, 2021 | 2.563 |
March 31, 2021 | 2.349 |
December 31, 2020 | 2.942 |
September 30, 2020 | 3.506 |
June 30, 2020 | 3.989 |
March 31, 2020 | 5.596 |
December 31, 2019 | 5.876 |
September 30, 2019 | 4.501 |
June 30, 2019 | 5.678 |
March 31, 2019 | 6.437 |
December 31, 2018 | 1.048 |
September 30, 2018 | 0.9694 |
June 30, 2018 | 1.058 |
March 31, 2018 | 0.8052 |
December 31, 2017 | 1.177 |
Date | Value |
---|---|
September 30, 2017 | 0.9043 |
June 30, 2017 | 0.8731 |
March 31, 2017 | 0.7303 |
December 31, 2016 | 0.7357 |
September 30, 2016 | 0.5997 |
June 30, 2016 | 0.6375 |
March 31, 2016 | 0.5414 |
December 31, 2015 | 0.5475 |
September 30, 2015 | 0.5308 |
June 30, 2015 | 0.5453 |
March 31, 2015 | 0.551 |
December 31, 2014 | 0.5218 |
September 30, 2014 | 0.3173 |
June 30, 2014 | 0.2953 |
March 31, 2014 | 0.2871 |
December 31, 2013 | 0.2957 |
September 30, 2013 | 0.3128 |
June 30, 2013 | 0.349 |
March 31, 2013 | 0.3652 |
December 31, 2012 | 0.3746 |
September 30, 2012 | 0.3436 |
June 30, 2012 | 0.385 |
March 31, 2012 | 0.365 |
December 31, 2011 | 0.516 |
September 30, 2011 | 0.4701 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
1.525
Minimum
Dec 2022
5.876
Maximum
Dec 2019
2.918
Average
2.342
Median
Dec 2023
Debt to Equity Ratio Benchmarks
Amgen Inc | 10.37 |
Biogen Inc | 0.4688 |
Madrigal Pharmaceuticals Inc | -- |
Vertex Pharmaceuticals Inc | 0.00 |
Viking Therapeutics Inc | -- |
Debt to Equity Ratio Related Metrics
Total Assets (Quarterly) | 64.01B |
Total Liabilities (Quarterly) | 53.14B |
Shareholders Equity (Quarterly) | 10.77B |
Current Ratio | 0.9426 |
Net Debt Paydown Yield | -0.34% |